You searched for "safety"
How good does my vision have to be to drive this thing? Visual standards for various occupations
2 August 2022
| Myles Potter
|
EYE - General
We can all picture that moment in clinic: you are about to tell someone that they’re no longer legally able to drive, ready to deploy our ‘breaking bad news’ techniques. For some patients this may have been expected, or they...
Ombudsman responds to Letby verdict
Parliamentary and Health Service Ombudsman, Rob Behrens, comments on the verdict in the trial of Lucy Letby.
Low cost drainage device use in paediatric glaucoma
1 October 2018
| Jonathan Chan
|
EYE - Glaucoma
|
Baerveldt, Childhood Glaucoma, Glaucoma Drainage Device
This is a prospective study from a tertiary referral centre from India of 34 eyes (31 patients) under 16 years with uncontrolled refractory glaucoma with medical treatment. A low cost glaucoma drainage device (GDD) – Aurolab aqueous drainage implant (ADDI),...
Moorfields medical retina: design thinking and service delivery of intravitreal injection service
19 September 2025
The Medical Retina service is constantly evolving and developing due to a rise in disease prevalence and treatment evolution. This unique course is especially designed for managers and clinical leaders in medical retina services. The course draws on the strength...
Moorfields to start new retinal detachment clinical trial
8 November 2023
|
Moorfields, Funding, Phase I trial, Mahi Muqit, retinal detachment, proliferative vitreoretinopathy
Moorfields to start new retinal detachment clinical trial following £1.2 million MRC DPFS grant awarded to UCL and Moorfields Eye Hospital.
Running a high-volume nurse led intravitreal service using the Sp.eye device – the Stanley Eye Unit experience
2 February 2024
| Julia Baxter, Eoin Guerin, Catrin Bertalot, Alison Birch, Tracy Turner, Karen Evans
|
EYE - Vitreo-Retinal
Introduction The vast majority of ophthalmology units utilise allied healthcare professionals (AHPs) to deliver intravitreal injections (IVIs). The Royal College of Ophthalmologists issued a statement 10 years ago advocating the use of non-medical practitioners performing IVIs [1]. The main benefit...
Ptosis surgery outcomes
The purpose of this study was to evaluate the long-term outcomes of childhood ptosis surgery in a population-based cohort. The authors assessed reoperation rates, amblyopia, risk of lag, dry eye and other complications. This was a retrospective review of 47...
LASEK vs. epi-LASIK for myopia: meta-analysis
1 October 2014
| Anjali Gupta
|
EYE - Cataract, EYE - Refractive
|
Epi-LASIK, LASEK, meta-analysis, myopia
Previous studies have produced inconsistent conclusions on the relative benefits between LASEK vs. Epi-LASIK. LASEK uses 20% alcohol to separate an epithelial flap from the Bowman membrane. After ablation, the epithelial flap is repositioned onto the cornea. Epi-LASIK creates the...
Lucentis for pseudophakic CMO
1 October 2015
| Saruban Pasu
|
EYE - Vitreo-Retinal
Pseudophakic cystoid macular oedema (CMO) develops angiographically in up to 20-30% after uneventful phacoemulsification. This study aimed to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic CMO after cataract surgery. Seven eyes were included in...
Pars plana vitrectomy for vitreomacular traction syndrome
1 December 2013
| Nikolaos D Georgakarakos
|
EYE - Vitreo-Retinal
This paper presents a meta-analysis and systematic review of the safety and efficacy of vitrectomy for vitreomacular traction (VMT), based on 21 eligible articles from 460 identified. A strength of this study is that it provided pooled analysis across a...
Long-term treatment of blepharospasm using Botulinum Toxin A
1 April 2020
| Claire Howard
|
EYE - Neuro-ophthalmology
The authors report findings from a retrospective single-centre study which aimed to evaluate the efficacy and safety of long-term botulinum A toxin (BAT) treatment in patients with blepharospasm (BPS). Blepharospasm is described as one of the most frequent types of...
Long-term use of botulinum toxin for hemifacial spasm and blepharospasm
1 February 2022
| Claire Howard
|
EYE - Neuro-ophthalmology
|
Botulinum neurotoxin, benign essential blepharospasm, hemifacial spasm, tolerance
The authors conducted a retrospective review of clinical / procedure documentation for consecutive blepharospasm (BEB) and hemifacial spasm (HFS) patients undergoing treatment with onabotulinum toxin A (Botox) in one clinic setting over the past 20 years. They report on the...
